Similar Products:
Azarest 300 mg Tablet contains Azacitidine, an anticancer medicine used to treat myelodysplastic syndromes (MDS) and certain types of leukemia. It helps improve bone marrow function and slows the growth of abnormal blood cells under specialist supervision.
Improves production of healthy blood cells
Reduces transfusion requirement
Slows disease progression
Enhances quality of life in MDS patients
Convenient oral formulation for long-term therapy
Azarest 300 mg Tablet is indicated for:
Myelodysplastic Syndromes (MDS)
Chronic Myelomonocytic Leukemia (CMML)
Acute Myeloid Leukemia (AML) (selected patients)
Patients with ineffective or insufficient blood cell production
Azacitidine reduces abnormal DNA methylation, restoring normal gene expression and slowing the uncontrolled growth of immature blood cells. This helps the bone marrow produce healthier and more functional blood cells.
Dose determined individually by the oncologist
Swallow tablet whole with water
Follow exact treatment cycles prescribed
Do not crush or chew the tablet
Regular blood tests required to monitor counts and organ function
Avoid missed doses for best results
Use only under medical supervision.
Common side effects:
Nausea, vomiting
Fatigue or weakness
Diarrhea or constipation
Loss of appetite
Low blood counts (neutropenia, anemia, thrombocytopenia)
Serious side effects (seek urgent care):
Severe infection or fever
Unusual bleeding or bruising
Kidney or liver impairment
Allergic reactions
Shortness of breath or chest discomfort
Not safe during pregnancy or breastfeeding May cause severe bone marrow suppression — monitor counts regularly Caution in patients with kidney or liver problems Avoid contact with sick individuals due to infection risk Report immediately: Fever or persistent infection Unexplained bleeding Extreme fatigue Yellowing of skin/eyes Chest pain or breathing issues Inform doctor about all chemotherapy or immunosuppressive medicines
Related Products
The realization that you or someone close to you needs a bone marrow transplant can be extremely daunting. It may
READ MORE »The U.S. Food and Drug Administration (FDA) has approved Ruxolitinib tablets for the treatment of certain hematologic malignancies, marking another
READ MORE »n Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 14, 2026.n n This marks an important
READ MORE »Only logged in customers who have purchased this product may leave a review.
Reviews
Clear filtersThere are no reviews yet.